Impact of statin use on heart failure mortality

Thambidorai, Senthil; Deshmukh, Anand; Walters, Ryan W.; Turner, Paul; Monaghan, Michael S.; Mooss, Aryan N.; Hunter, Claire; Esterbrooks, Dennis J.; Mohiuddin, Syed M.

doi:10.1016/j.ijcard.2010.08.016

Cited by 16 publications

(25 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, down-regulation of the SERCA2 activity by 26.4 % (p < 0.05) was observed (Table II). Previous studies have shown that statins can restore heart function in ischemic or non-ischemic cardiomyopathy (8,11), ameliorate BNP up-regulation (10), down-regulate arrhythmic events (6) and reduce sudden cardiac death (21) in addition to their lipid--lowering effects. Our present study also demonstrated that pitavastatin could ameliorate cardiac malfunction in DCM mice, especially in the high dose group (p < 0.05) (Figs.…”

Section: Resultsmentioning

confidence: 99%

Pitavastatin-attenuated cardiac dysfunction in mice with dilated cardiomyopathy via regulation of myocardial calcium handling proteins

Hu¹,

Jiang²

2014

Acta Pharmaceutica

View full text Add to dashboard Cite

Dilated cardiomyopathy (DCM) is a multifactorial disease involving cardiac dysfunction and enlargement of one or of both ventricles (1). A number of new anti-heart failure medications, even cytokine therapy (2) or stem cell transplantation (3) have been developed (4) C57BL/6 mice with dilated cardiomyopathy (DCM) were randomly divided to receive placebo or pitavastatin at a dose of 1 or 3 mg kg -1 d -1 . After 8 weeks treatment, mice with dilated cardiomyopathy developed serious cardiac dysfunction characterized by significantly enhanced left ventricular end-diastolic diameter (LVIDd), decreased left ventricular ejection fraction (LVEF) as well as left ventricular short axis fractional shortening (LVFS), accompanied with enlarged cardiomyocytes, and increased plasma levels of N-terminal pro-B type natriuretic peptide (NT-proBNP) and plasma angiotensin II (AngII) concentration. Moreover, myocardium sarcoplasmic reticulum Ca 2+ pump (SERCA-2) activity was decreased. The ratio of phosphorylated phospholamban (PLB) to total PLB decreased significantly with the down-regulation of SERCA--2a and ryanodine receptor (RyR2) expression. Pitavastatin was found to ameliorate the cardiac dysfunction in mice with dilated cardiomyopathy by reversing the changes in the ratios of phosphorylated PLB to total PLB, SERCA-2a and RyR2 via reducing the plasma AngII concentration and the expressions of myocardium angiotensin II type 1 receptor (AT 1 R) and protein kinase C (PKC)b2. The possible underlying mechanism might be the regulation of myocardial AT 1 R-PKCb2-Ca 2+ handling proteins.

show abstract

Section: Resultsmentioning

confidence: 99%

Pitavastatin-attenuated cardiac dysfunction in mice with dilated cardiomyopathy via regulation of myocardial calcium handling proteins

Hu¹,

Jiang²

2014

Acta Pharmaceutica

View full text Add to dashboard Cite

show abstract

“…Heart failure was most consistently associated with all types of lipid abnormalities independent of statin treatment. Several observational studies have shown statins to be associated with reduced mortality in patients with heart failure [25]; while some randomized controlled statin trials have shown a reduction in hospitalization and improved markers [26,27,28,29], they have not demonstrated mortality in this patient population [27,29]. Factors associated with mortality in patients with heart failure are complex and are beyond the scope of this observational study.…”

Section: Discussionmentioning

confidence: 99%

Total Lipid Management and Cardiovascular Disease in the Dyslipidemia International Study

et al. 2013

View full text Add to dashboard Cite

Objectives: Despite statin use, many patients with cardiovascular disease (CVD) are not achieving treatment goals. An international observational study was performed to estimate the prevalence of residual lipid abnormalities in statin-treated patients with CVD to assess whether lipid management requires improvement. Methods: Fasting plasma concentrations of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides were recorded in 11,104 patients with atherosclerotic CVD and ≥3 months of statin therapy. Results: LDL-C and total cholesterol were not at goal levels in 41 and 46% of all patients, respectively; for patients with peripheral artery disease (PAD) only, 59 and 65%, respectively, were not at goal, and in those with coronary heart disease only, 38 and 42%, respectively, were not at goal. Patients with cerebrovascular disease only were least frequently observed to have low HDL-C (24%) and elevated triglycerides (36%). Overall, elevated LDL-C was the most frequent lipid anomaly observed, and preexisting heart failure was strongly and positively associated with dyslipidemia. Conclusions: Approximately two fifths of statin-treated patients with CVD are not reaching lipid goals or have abnormal lipid levels, while patients with PAD could particularly benefit from improved lipid management. In addition to targeting LDL-C, new evidence-based approaches are needed to target low HDL-C and elevated triglycerides.

show abstract

“…We have greatly enjoyed reading the recently published letter by Topatan and Başaran [1] related with CA-125 and heart failure. In this report, the authors commented on an article related with the prognostic value of CA-125 in patients with advanced heart failure [2].…”

Section: Dear Editormentioning

confidence: 99%

“…Besides, in the study of Yilmaz et al [4], patients with high CA-125 levels were shown to have more frequent hospitalization and mortality. Although, in the manuscript [1], the authors primarily focused on the mesothelium as the primary source of CA-125, from recent articles [5][6][7][8][9][10], we have learned a lot about the pathophysiological link of CA-125 in heart failure. CA-125 levels were shown to be related with the serum TNF-alpha, IL-6 and IL-10 levels, and hence pathobiological link might possibly be driven through cytokines [9].…”

Section: Dear Editormentioning

confidence: 99%

See 1 more Smart Citation

Statin dilemma in the management of chronic heart failure

Çelik¹,

Demırkol²

2011

International Journal of Cardiology

View full text Add to dashboard Cite

Impact of statin use on heart failure mortality

Abstract: Veterans who were not exposed to statin therapy at any time during the study period were 1.56 times more likely to suffer all-cause mortality.

Cited by 16 publications

References 29 publications

Pitavastatin-attenuated cardiac dysfunction in mice with dilated cardiomyopathy via regulation of myocardial calcium handling proteins

Pitavastatin-attenuated cardiac dysfunction in mice with dilated cardiomyopathy via regulation of myocardial calcium handling proteins

Total Lipid Management and Cardiovascular Disease in the Dyslipidemia International Study

Statin dilemma in the management of chronic heart failure

Contact Info

Product

Resources

About